Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ElevatION: CRC-101
NCT03176264Phase 1Terminated
- Sponsor
- Novartis
- Start
- Sep 2017
- Primary completion
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of spartalizumab in colorectal cancer (CRC), sponsored by Novartis. Primary endpoints: Incidence of Dose-limiting toxicity at 12 months and Overall Response Rate at 19 months. Started Sep 2017; status: terminated.
02
Drugs
spartalizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03176264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03176264.